WHO vaccine-preventable diseases: monitoring system. 2016 global summary

Last updated 15-July-2016 (15-July-2016)
Next overall update Fall 2016
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 47'6401 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 43'3931 Child (under 5 years) mortality rate: 22

Population data in thousands3

  2015  2014  2013  2012  2011  2000  1990  1980 
Total population 329  327  325  323  321  281  255  228 
Births
Surviving infants
Pop. less than 5 years 23  23  24  24  24  21  21  21 
Pop. less than 15 years 67  67  67  67  67  65  64  63 
Female 15-49 years 77  77  78  78  78  72  65  56 

Number of reported cases

(Click for retrospective incidence data for Iceland)
Diphtheria
ChartChart
 
Japanese encephalitis
ChartChart
 
Measles
ChartChart ChartChart
  14  13 
Mumps
ChartChart
  71 
Pertussis
ChartChart
  31  36  41 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For desagregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Iceland)
Vaccine year result method % card seen                                                
BCG         
DTP1          96  96  97  97  99  99 
DTP3          92  90  91  89  95  98  99 
DTP4          91  84 
IPV1          96 
HepB_BD         
HepB3         
Hib3          92  90  91  89  95  98 
JapEnc         
MCV1          93  90  91  90  94  91  99 
MCV2          94  93  94  97  90 
PCV1          95  96  96  96  89 
PCV3          91  90  89  86 
Pol3          92  90  91  89  95  98  99 
Rota1         
RotaC         
Rubella1          93  90  91  90  94 
TT2plus         
PAB         
VAD1         
YFV         
° indicates that more than 1 survey occurred that year.  * indicates the country reported above 100% coverage.

  Next update: Mid July 2017

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Iceland)
DTP1
ChartChart
  96  96  97  97  99  99  99  99 
DTP3
ChartChart
  92  90  91  89  95  98  99  99 
HepB3
ChartChart
 
HepB_BD
ChartChart
 
Hib3
ChartChart
  92  90  91  89  95  98 
MCV1
ChartChart
  93  90  91  90  94  91  99 
MCV2
ChartChart
  94  93  94  97  90 
PCV3
ChartChart
  91  90  88  86 
Pol3
ChartChart
  92  90  91  89  95  98  99  99 
RCV1
ChartChart
  93  90  91  90  94  91  99 
RotaC
ChartChart
 

Number of districts in the country 59  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2015 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibIPV 3, 5, 12 months; Yes
DTaPIPV 14 years; Yes
HPV 12 years; +2 months; Yes
HepA Yes travellers
HepB_Adult Yes risk groups and travellers
HepB_Pediatric Yes risk groups and travellers
Influenza_Adult >= 60 years; Yes and adults with chronic diseases, pregnant women, health care workers
Influenza_Pediatric Yes Children with chronic diseases
MMR 18 months; 12 years; Yes
MenACWY Yes travellers
MenC_conj 6, 8 months; Yes
Pneumo_conj 3, 5, 12 months; Yes
Pneumo_ps Yes risk groups
Rubella Yes women at risk
TdaPIPV Yes travellers
Tdap 4 years; Yes
Typhoid Yes travellers
Varicella Yes voluntary
YF Yes travellers

Immunizaton indicators

Indicator Expected answer 2015  2014  2013  2012  2011  2010  2009 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  NA  NA 
What years does the MYP cover? number 2010-2020             
Nº of districts with microplans that include activities to raise immunization coverage number 59  59  59  59  59     

System performance

Total Nº districts in country number 59  59  59  59  59  59  59 
Nº districts with DTP3 coverage >=80% number         59  59  59 
% of districts with DTP3 coverage >=80% From 0 to 100%         100  100  100 
Nº districts with measles (MCV1) coverage >=95% number NA  NA       
% of districts with MCV1 coverage >=95% From 0 to 100%          

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  No   
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes   

Sources

 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2015 revision". New York, 2016.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.